These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29255995)

  • 1. Effectiveness of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Physical Injuries: A Systematic Review and Meta-Analysis of Observational Studies.
    Man KKC; Ip P; Chan EW; Law SL; Leung MTY; Ma EXY; Quek WT; Wong ICK
    CNS Drugs; 2017 Dec; 31(12):1043-1055. PubMed ID: 29255995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
    Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
    JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study.
    Dalsgaard S; Leckman JF; Mortensen PB; Nielsen HS; Simonsen M
    Lancet Psychiatry; 2015 Aug; 2(8):702-709. PubMed ID: 26249301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes.
    Chang Z; Quinn PD; Hur K; Gibbons RD; Sjölander A; Larsson H; D'Onofrio BM
    JAMA Psychiatry; 2017 Jun; 74(6):597-603. PubMed ID: 28492937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design.
    Raman SR; Marshall SW; Haynes K; Gaynes BN; Naftel AJ; Stürmer T
    Inj Prev; 2013 Jun; 19(3):164-70. PubMed ID: 23143347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV; Glatt SJ
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
    Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
    PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender and injuries predict stimulant medication use.
    Dalsgaard S; Leckman JF; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):253-9. PubMed ID: 24813570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication therapy for attention deficit/hyperactivity disorder is associated with lower risk of fracture: a retrospective cohort study.
    Perry BA; Archer KR; Song Y; Ma Y; Green JK; Elefteriou F; Dahir KM
    Osteoporos Int; 2016 Jul; 27(7):2223-2227. PubMed ID: 26928186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects.
    Hart H; Radua J; Nakao T; Mataix-Cols D; Rubia K
    JAMA Psychiatry; 2013 Feb; 70(2):185-98. PubMed ID: 23247506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
    Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D;
    BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients.
    Cunill R; Castells X; Tobias A; Capellà D
    Psychopharmacology (Berl); 2016 Jan; 233(2):187-97. PubMed ID: 26446868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: protocol for a systematic review and meta-analysis.
    Ruiz-Goikoetxea M; Cortese S; Aznarez-Sanado M; Magallon S; Luis EO; Álvarez Zallo N; Castro-Manglano P; Soutullo C; Arrondo G
    BMJ Open; 2017 Sep; 7(9):e018027. PubMed ID: 28951416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.
    Pringsheim T; Steeves T
    Cochrane Database Syst Rev; 2011 Apr; (4):CD007990. PubMed ID: 21491404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician Office Visits for Attention-deficit/Hyperactivity Disorder in Children and Adolescents Aged 4-17 Years: United States, 2012-2013.
    Albert M; Rui P; Ashman JJ
    NCHS Data Brief; 2017 Jan; (269):1-8. PubMed ID: 28135186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis.
    Ruiz-Goikoetxea M; Cortese S; Aznarez-Sanado M; Magallón S; Alvarez Zallo N; Luis EO; de Castro-Manglano P; Soutullo C; Arrondo G
    Neurosci Biobehav Rev; 2018 Jan; 84():63-71. PubMed ID: 29162520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.
    Zhang L; Yao H; Li L; Du Rietz E; Andell P; Garcia-Argibay M; D'Onofrio BM; Cortese S; Larsson H; Chang Z
    JAMA Netw Open; 2022 Nov; 5(11):e2243597. PubMed ID: 36416824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.
    Tsujii N; Okada T; Usami M; Kuwabara H; Fujita J; Negoro H; Kawamura M; Iida J; Saito T
    J Clin Psychiatry; 2020 Mar; 81(3):. PubMed ID: 32237294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.